A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Dantrium Patient, Information, Instructions - Dantrolene Sodium
Dantrium Patient, Information, Instructions - Dantrolene Sodium
PATIENT INFORMATION
Based upon data in human volunteers, it will sometimes be appropriate
to tell patients who receive Dantrium Intravenous that decrease in grip
strength and weakness of leg muscles, especially walking down stairs,
can be expected postoperatively. In addition, symptoms such as “lightheadedness”
may be noted. Since some of these symptoms may persist for up to 48 hours,
patients must not operate an automobile or engage in other hazardous activity
during this time. Caution is also indicated at meals on the day of administration
because difficulty swallowing and choking has been reported. Caution should
be exercised in the concomitant administration of tranquilizing agents.
Hepatotoxicity seen with Dantrium Capsules: Dantrium (dantrolene
sodium) has a potential for hepatotoxicity, and should not be used in
conditions other than those recommended. Symptomatic hepatitis (fatal
and non-fatal) has been reported at various dose levels of the drug. The
incidence reported in patients taking up to 400 mg/day is much lower than
in those taking doses of 800 mg or more per day. Even sporadic short courses
of these higher dose levels within a treatment regimen markedly increased
the risk of serious hepatic injury. Liver dysfunction as evidenced by
blood chemical abnormalities alone (liver enzyme elevations) has been
observed in patients exposed to Dantrium for varying periods of time.
Overt hepatitis has occurred at varying intervals after initiation of
therapy, but has been most frequently observed between the third and twelfth
month of therapy. The risk of hepatic injury appears to be greater in
females, in patients over 35 years of age, and in patients taking other
medication(s) in addition to Dantrium (dantrolene sodium). Dantrium should
be used only in conjunction with appropriate monitoring of hepatic function
including frequent determination of SGOT or SGPT.
Fatal and non-fatal liver disorders of an idiosyncratic or hypersensitivity
type may occur with Dantrium therapy.
top
